Sandesh Mahatme
2017
In 2017, Sandesh Mahatme earned a total compensation of $2.2M as Executive Vice President, Chief Financial Officer and Chief Business Officer at Sarepta Therapeutics, a 22% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $257,181 |
|---|---|
| Option Awards | $601,433 |
| Salary | $459,252 |
| Stock Awards | $867,827 |
| Other | $14,440 |
| Total | $2,200,133 |
Mahatme received $867.8K in stock awards, accounting for 39% of the total pay in 2017.
Mahatme also received $257.2K in non-equity incentive plan, $601.4K in option awards, $459.3K in salary and $14.4K in other compensation.
Rankings
In 2017, Sandesh Mahatme's compensation ranked 5,058th out of 14,666 executives tracked by ExecPay. In other words, Mahatme earned more than 65.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,058 out of 14,666 | 66th |
Division Manufacturing | 1,802 out of 5,772 | 69th |
Major group Chemicals And Allied Products | 532 out of 2,075 | 74th |
Industry group Drugs | 410 out of 1,731 | 76th |
Industry Pharmaceutical Preparations | 325 out of 1,333 | 76th |
Source: SEC filing on April 26, 2018.
Mahatme's colleagues
We found six more compensation records of executives who worked with Sandesh Mahatme at Sarepta Therapeutics in 2017.
2017
Douglas Ingram
Sarepta Therapeutics
Chief Executive Officer
2017
Edward Kaye
Sarepta Therapeutics
Chief Executive Officer
2017
Guriqbal Basi
Sarepta Therapeutics
Chief Scientific Officer
2017
Alexander Cumbo
Sarepta Therapeutics
Senior Vice President, Chief Commercial Officer
2017
David Howton
Sarepta Therapeutics
General Counsel
2017
Catherine Stehman-Breen
Sarepta Therapeutics